Carfilzomib Combined with Thalidomide and Dexamethasone (CTD) Is an Highly Effective Induction and Consolidation Treatment in Newly Diagnosed Patients with Multiple Myeloma (MM) Who Are Transplant Candidate

被引：0

作者：

Sonneveld, Pieter ^{[1
]}

Asselbergs, Emilie ^{[1
]}

Zweegman, Sonja ^{[2
]}

Van der Holt, Bronno ^{[3
]}

Kersten, Marie Jose ^{[4
]}

Vellenga, Edo ^{[5
]}

van Marwijk-Kooy, Marinus ^{[6
]}

de Weerdt, Okke ^{[7
]}

Lonergan, Sarah

Lokhorst, Henk ^{[8
]}

机构：

[1] Erasmus MC, Rotterdam, Netherlands

[2] Vrije Univ Amsterdam Med Ctr, Dept Hematol, Amsterdam, Netherlands

[3] Erasmus MC, HOVON Data Ctr, Rotterdam, Netherlands

[4] AMC, Amsterdam, Netherlands

[5] Univ Med Ctr Groningen UMCG, Groningen, Netherlands

[6] Isala Clin, Zwolle, Netherlands

[7] St Antonius Hosp, Dept Internal Med, Nieuwegein, Netherlands

[8] Univ Med Ctr Utrecht, Dept Hematol, Utrecht, Netherlands

来源：

BLOOD | 2012年 / 120卷 / 21期

关键词：

D O I：

10.1182/blood.V120.21.333.333

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

333

引用

页数：2

共 50 条

[1] Carfilzomib Combined with Thalidomide and Low-Dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma: The Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooij, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique C.
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broyl, Annemiek
Iskander, Karim Saad
Sonneveld, Pieter
BLOOD, 2017, 130
[2] Phase 2 study of carfilzomib, thalidomide, and dexamethasone as induction/consolidation therapy for newly diagnosed multiple myeloma
Sonneveld, Pieter
Asselbergs, Emilie
Zweegman, Sonja
van der Holt, Bronno
Kersten, Marie Jose
Vellenga, Edo
van Marwijk-Kooy, Marinus
Broyl, Annemiek
de Weerdt, Okke
Lonergan, Sarah
Palumbo, Antonio
Lokhorstl, Henk
BLOOD, 2015, 125 (03) : 449 - 456
[3] Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
Wester, Ruth
Zweegman, Sonja
van der Holt, Bronno
Kersten, Marie Jose
Vellenga, Edo
van Marwijk-Kooy, Marinus
Asselbergs, Emelie
de Weerdt, Okke
Minnema, Monique C.
Lonergan, Sarah
Palumbo, Antonio
Broijl, Annemiek
Sonneveld, Pieter
HEMASPHERE, 2020, 4 (04):
[4] Phase 2 Study of Carfilzomib, Thalidomide, and Low-Dose Dexamethasone As Induction/Consolidation in Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma, the Carthadex Trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
van Duin, Mark
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk M.
Broijl, Annemiek
Sonneveld, Pieter
BLOOD, 2016, 128 (22)
[5] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
Wester, Ruth
van der Holt, Bronno
Asselbergs, Emelie
Zweegman, Sonja
Kersten, Marie Jose
Vellenga, Edo
Kooy, Marinus van Marwijk
de Weerdt, Okke
Minnema, Monique
Lonergan, Sarah
Palumbo, Antonio
Lokhorst, Henk
Broijl, Annemiek
Sonneveld, Pieter
HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273
[6] CYCLOPHOSPHAMIDE, THALIDOMIDE AND DEXAMETHASONE (CTD) AS INITIAL THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Vasquez, J.
Ruiz, R.
Aliaga, K.
Valencia, F.
Enriquez, D.
Palacios, V.
Quintana, S.
Casanova, L.
HAEMATOLOGICA, 2016, 101 : 798 - 798
[7] Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients
Palumbo, Antonio
Bringhen, Sara
Villani, Oreste
Siniscalchi, Agostina
Russo, Eleonora
Uccello, Giuseppina
Cerrato, Chiara
Gilestro, Milena
Rossi, Davide
Boccadoro, Mario
BLOOD, 2012, 120 (21)
[8] Carfilzomib and dexamethasone induction with lenalidomide, clarithromycin and dexamethasone consolidation and lenalidomide maintenance for newly diagnosed multiple myeloma
Forsberg, Peter A.
Rossi, Adriana C.
Boyer, Angelique
Pearse, Roger N.
Pekle, Karen A.
Jayabalan, David
Lakritz, Stephanie
Flicker, Kari
Ribadeneyra, Drew
Liotta, Brielle
Ely, Scott
Boussi, Leora
Allan, John N.
Coleman, Morton
Niesvizky, Ruben
Mark, Tomer M.
AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (12) : 1554 - 1562
[9] Cyclophosphamide, thalidomide and dexamethasone (CTD) as initial therapy for newly diagnosed multiple myeloma patients.
Chavez, Jule Franve Vasquez
Mendoza, Rossana Esther Ruiz
Llerena, Karina Mayra Aliaga
Valencia, Fernando
Enriquez, Daniel
Palacios, Victor
Casanova, Luis
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[10] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, Jagoda K.
Kubicki, Tadeusz
Raje, Noopur
Vij, Ravi
Reece, Donna
Berdeja, Jesus
Derman, Benjamin A.
Rosenbaum, Cara A.
Richardson, Paul
Gurbuxani, Sandeep
Major, Sarah
Wolfe, Brittany
Stefka, Andrew T.
Stephens, Leonor
Tinari, Kathryn M.
Hycner, Tyler
Rojek, Alexandra E.
Dytfeld, Dominik
Griffith, Kent A.
Zimmerman, Todd M.
Jakubowiak, Andrzej J.
BLOOD, 2020, 136 (22) : 2513 - 2523

← 1 2 3 4 5 →